SAFE (Sarpogrelate Anplone in Femoro-popliteal Artery Intervention Efficacy) Study
Status:
Unknown status
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
After endovascular treatment (EVT) for peripheral artery disease (PAD), dual antiplatelet
therapy (DAAT) of aspirin (ASA) and clopidogrel are currently drug of choice to prevent
occlusion. Anplone SR®, controlled-released Sarpogrelate hydrochloride, has been introduced
as an anti-platelet agent for the drug of PAD. The aim of this study was to compare the
efficacy and safety of Anplone + aspirin and clopidogrel + aspirin in patients who underwent
EVT for femoro-popliteal occlusive disease.